Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’View Video
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin AmericaView Video

Latest Share Chat

Pin to quick picksMTFB.L Regulatory News (MTFB)

  • There is currently no data for MTFB

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Exercise of Warrants

15 May 2020 07:00

RNS Number : 9759M
Motif Bio PLC
15 May 2020
 

 

Motif Bio plc

("Motif Bio" or the "Company")

 

Exercise of Warrants

 

Motif Bio plc (AIM: MTFB), which has been reclassified as an AIM Rule 15 cash shell, announces that it has received notification from a warrant holder to exercise warrants representing 7,142,857 ordinary shares of 0.01p each ("Ordinary Shares") in the Company for total consideration of £48,571.43. The exercise price of all warrants was 0.68p per warrant.

 

Application has been made for the 7,142,857 new Ordinary Shares to be admitted to trading on AIM ("Admission"), which is expected to occur at 8.00 a.m. on 20 May 2020. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. The Company does not hold any Ordinary Shares in treasury.

 

Following Admission, and further to the announcement made on 5 May 2020, and for the purposes of the Disclosure Guidance and Transparency Rules, the Company's total issued share capital will consist of 654,991,023 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

 

For further information please contact:

 

 

Motif Bio plc

 

ir@motifbio.com

Jonathan Gold (President and Chief Business Officer)

 

 

 

SP Angel Corporate Finance LLP (NOMAD & BROKER)

+44 (0)20 3470 0470

David Hignell/Caroline Rowe (Corporate Finance)

 

Vadim Alexandre/Abigail Wayne (Sales & Broking)

 

 

 

Walbrook PR Ltd. (UK FINANCIAL PR & IR)

+44 (0)20 7933 8780

Paul McManus/ Lianne Cawthorne

motifbio@walbrookpr.com

 

 

Forward-Looking Statements

When used in this Press Release, the words or phrases "intends," "anticipates," "expected to be" or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties including, but not limited to, changes in economic conditions in the Company's market area, changes in policies by regulatory agencies, fluctuations in interest rates, competition that could cause actual results to differ materially from historical earnings and those presently anticipated or projected, and other risks described in the Company's filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The Company advises readers that the factors listed above could affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed with respect to future periods in any current statements. The Company does not undertake, and specifically disclaims any obligation, to publicly release the result of any revision which may be made to any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
IOESFEFMLESSEFI
Date   Source Headline
30th Sep 20194:35 pmRNSPrice Monitoring Extension
30th Sep 20192:22 pmRNSHalf-year Report
17th Sep 20194:41 pmRNSSecond Price Monitoring Extn
17th Sep 20194:35 pmRNSPrice Monitoring Extension
4th Sep 20192:57 pmRNSHolding(s) in Company
2nd Sep 20197:00 amRNSAmended Loan and Security Agreement
30th Aug 20194:41 pmRNSSecond Price Monitoring Extn
30th Aug 20194:35 pmRNSPrice Monitoring Extension
19th Aug 20197:00 amRNSNIH to Evaluate Iclaprim Activity against Listeria
1st Aug 20197:00 amRNSAmended Loan and Security Agreement
26th Jul 20197:00 amRNSMotif Bio Confirms Meeting Date with U.S. FDA
26th Jul 20197:00 amRNSReceipt of Deficiency Notice from Nasdaq
19th Jul 20197:00 amRNSMotif Bio-Receipt of Deficiency Notice from Nasdaq
18th Jul 20194:30 pmRNSHolding(s) in Company
15th Jul 20197:00 amRNSUS FDA meeting request and package submitted
28th Jun 20195:13 pmRNSHolding(s) in Company
28th Jun 20194:40 pmRNSSecond Price Monitoring Extn
28th Jun 20194:36 pmRNSPrice Monitoring Extension
26th Jun 201912:07 pmRNSSecond Price Monitoring Extn
26th Jun 201912:02 pmRNSPrice Monitoring Extension
24th Jun 20197:00 amRNSMotif Bio Presents New Iclaprim Data - ASM Microbe
20th Jun 20194:35 pmRNSPrice Monitoring Extension
19th Jun 20195:08 pmRNSHolding(s) in Company
18th Jun 20194:05 pmRNSHolding(s) in Company
14th Jun 20199:04 amRNSHolding(s) in Company
12th Jun 20195:52 pmRNSHolding(s) in Company
6th Jun 20197:00 amRNSReceipt of FDA Meeting Minutes
31st May 20193:15 pmRNSResult of AGM
31st May 201910:28 amRNSHolding(s) in Company
29th May 201911:36 amRNSHolding(s) in Company
22nd May 20191:50 pmRNSAGM Statement
22nd May 20197:00 amRNSOrphan Disease Opportunity for Iclaprim
21st May 20197:00 amRNSIclaprim Data presented at ASM Microbe 2019
20th May 20196:14 pmRNSHolding(s) in Company
3rd May 20196:25 pmRNSMeeting with US FDA held as planned
1st May 20197:00 amRNSMotif Signs Agreement with Lamellar Biomedical
26th Apr 20197:01 amRNSNotice of AGM
26th Apr 20197:00 amRNSAppointment of Andrew Powell to Board of Directors
16th Apr 20197:00 amRNSMotif Presents New Iclaprim Data at ECCMID 2019
15th Apr 20197:00 amRNSFiscal Year 2018 Results
4th Apr 20197:00 amRNSMotif Bio to Present Iclaprim Data at ECCMID 2019
2nd Apr 20195:43 pmRNSHolding(s) in Company
1st Apr 20193:28 pmRNSHolding(s) in Company
1st Apr 20192:17 pmRNSHolding(s) in Company
26th Mar 20197:00 amRNSMotif Bio Raises £2.7m (US$3.55m)
25th Mar 20199:49 amRNSProposed Equity Fundraise
20th Mar 20197:00 amRNSHolding(s) in Company
20th Mar 20197:00 amRNSMotif Bio Granted Meeting with U.S. FDA
18th Mar 20197:00 amRNSAppointment of Bruce Williams as Interim Chairman
15th Mar 20197:01 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.